Apolipoprotein A1 in Cerebrospinal Fluid Is Insufficient to Distinguish Alzheimer’s Disease from Other Dementias in a Naturalistic, Clinical Setting

  • Stoye N
  • Jung P
  • Guilherme M
  • et al.
N/ACitations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Apolipoprotein A1 (ApoA1) is the major protein component of the high-density lipoprotein and involved in cholesterol transport. Disruption of cholesterol homeostasis has been identified as a contributing factor for Alzheimer’s disease (AD). Moreover, polymorphisms of ApoA1 have been associated with higher risk of disease onset and cognitive decline. Therefore, ApoA1 has been suggested as a biomarker in AD. Here, we tested a small cohort of AD and non-AD dementia patients and measured levels of ApoA1 in cerebrospinal fluid. Our results indicate that ApoA1 might not be applicable to distinguish AD from other forms of dementia.

Cite

CITATION STYLE

APA

Stoye, N. M., Jung, P., Guilherme, M. dos S., Lotz, J., Fellgiebel, A., & Endres, K. (2020). Apolipoprotein A1 in Cerebrospinal Fluid Is Insufficient to Distinguish Alzheimer’s Disease from Other Dementias in a Naturalistic, Clinical Setting. Journal of Alzheimer’s Disease Reports, 4(1), 15–19. https://doi.org/10.3233/adr-190165

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free